Immunotherapy compliance: comparison of subcutaneous versus XXXX .

@entity1 @entity13366 @entity9285
BACKGROUND: @entity1 compliance is critical for successful allergen immunotherapy (AIT). Previous studies suggest that AIT compliance is worse outside of controlled clinical trials, with reported @entity9285 ( @entity9285 ) and @entity13366 ( @entity13366 ) noncompliance at 11% to 50% and 3% to 25%, respectively. METHODS: A retrospective review of 384 AIT @entity1 at a single, tertiary care otolaryngic allergy practice evaluated @entity9285 and @entity13366 compliance, based on treatment stage. @entity9285 compliance was defined as the number of 2-week breaks per year or in compliance with their defined schedule: excellent = 2 or fewer; good = 3 to 4; fair = 5 to 6; and poor = 7 or more. Compliance with @entity13366 was defined as the number of days vials were refilled within the defined expiration date: excellent = 10 days or fewer; good = 11 to 15 days, fair = 16 to 20 days; and poor = 25 or more days. Fisher exact and chi square tests were used for statistical analysis. RESULTS: Seventy-four @entity9285 and 200 @entity13366 @entity1 had data appropriate for analysis. Compliance rates were excellent (62%) or good (22%) in 62 @entity9285 @entity1 and excellent (31%) or good (35%) in 131 @entity13366 @entity1 . Comparing excellent compliance rates, @entity9285 @entity1 had a higher rate of excellent compliance at all stages of treatment compared to @entity13366 @entity1 (p < 0.05). For @entity9285 @entity1 there was no significant difference in excellent compliance rates between escalation, first year of maintenance, and greater than 1 year of maintenance (p > 0.05). CONCLUSION: The results of this study showed higher rates of @entity1 adherence to treatment protocols among @entity9285 @entity1 . There was no decrease in @entity9285 compliance rates across treatment stages.
